[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.5.239. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1957

Severe Hypotensive Crises Following Treatment with Meprobamate

Author Affiliations

Manchester, England

Department of Psychiatry, Manchester Royal Infirmary.

AMA Arch Intern Med. 1957;100(3):484-486. doi:10.1001/archinte.1957.00260090140020
Abstract

Meprobamate ( 2-methyl-2-n-propyl-1,3-propanediol dicarbamate), marketed in the United Kingdom as Equanil, Miltown, and Mepavlon, is in common use as a tranquilizer in psychiatric states characterized by anxiety and tension. Berger, from whose laboratories it comes, describes three pharmacological properties: a muscle-relaxant action, an anticonvulsant action, and a tranquilizing action. He states that it acts on the central nervous system only, without affecting autonomic functions; it seems to have a unique selective action on the thalamus.

Clinical evaluation is far from complete, but meprobamate seems to be more effective in neurotic than in psychotic conditions. It seemed to us to have two advantages over chlorpromazine: It acted much more quickly when given orally, and it was reported to have no troublesome complications, such as jaundice or agranulocytosis. Berger stated that drowsiness, seldom inconvenient, and infrequent allergic reactions were the only side-effects. More recently, however, Friedman and Marmelzat have described cutaneous, muscular, gastrointestinal,

First Page Preview View Large
First page PDF preview
First page PDF preview
×